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Oxidized low-density lipoprotein in experimental focal
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Oxidized low-density lipoprotem in experimental focal glomeruloscie-
rosis. Oxidized low-density lipoproteins (Ox-LDL) have been shown to
be involved in the pathogenesis of atherosclerosis. Because of the
similarities between atherosclerosis and focal glomeruloscierosis, a
study was performed to demonstrate whether Ox-LDL could be de-
tected in the glomeruli in experimental FGS. FGS was induced in 12
rats on a 4% cholesterol-1% choline diet by seven injections of
puromycin aminonucleoside over a 10 week period. Eight rats on a
normal diet served as controls. Fourteen weeks after the start of the
experiment all rats were sacrificed. The test animals showed marked
hypercholesterolemia and proteinuria. About 20% of glomeruli in test
animals showed FGS and variable amounts of glomerular lipid were
demonstrated. Immunohistochemical staining using five specific mono-
clonal antibodies against various forms of Ox-LDL showed positive
staining of a variable number of glomeruli in the test rats. The staining
pattern appeared to be intracellular. Staining with ED! showed signif-
icantly increased numbers of intraglomerular monocytes in the test rats
(test vs. control 2.4 1.1 vs. 0.4 0.1 monocytes per glomerulus, P <
0.0001). Control animals showed no segmental sclerosis, no glomerular
lipid, and no staining for Ox-LDL. Lipid analysis of isolated glomeruli
showed increased cholesterol, increased arachidonic acid and de-
creased eicosapentaenoic acid in test animals compared to controls.
The findings suggest a role for Ox-LDL in the pathogenesis of experi-
mental FGS and support the hypothesis that FGS is analogous to
atherosclerosis.
Human primary focal glomeruloscierosis (FGS) is a chronic
progressive disease that is often manifested by the nephrotic
syndrome, and frequently results in chronic renal failure. The
pathogenesis of this disease is uncertain but appears to be
multi-factorial [1]. There is considerable experimental and
human evidence to suggest the involvement of glomerular
capillary hypertension with hyperfiltration [2, 3], intraglomeru-
lar monocyte infiltration [4—7], hyperlipidemia and glomerular
lipid deposition [8—13], genetic factors [14], and coagulation
abnormalities [15, 16] in the development of FGS. Indeed, this
constellation of factors has led to the proposal that FGS is
analogous to atherosclerosis [8, 17].
Central to the development of atherosclerosis is the involve-
ment of lipid deposition in the walls of arteries, especially low
density lipoprotein (LDL) [18]. Recent experimental work
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suggests that the oxidation of LDL in vessel walls is a critical
step in the pathogenesis of atherosclerosis [19]. Apolipopro-
teins B and E have been demonstrated in the glomeruli of a
number of patients with FGS [20, 21]. However, to date there is
no evidence that oxidized LDL (Ox-LDL) is present in glomer-
uli in FGS, either human or experimental.
In view of the putative importance of Ox-LDL in atheroscle-
rosis and the concept of FGS being analogous to atherosclero-
sis, it is reasonable to hypothesize that Ox-LDL is involved in
the pathogenesis of FGS. The purposes of the present study are
to demonstrate the presence of Ox-LDL by immunohistochem-
ical means and to perform a biochemical analysis of glomerular
lipid in an experimental model of FGS.
Methods
Experimental design
FGS was induced in 12 male, 150 to 200 g Sprague-Dawley
rats (Group I) by seven subcutaneous injections of puromycin
aminonucleoside (20 mg/kg; Sigma Chemical Co., St. Louis,
Missouri, USA) over a 10 week period according to a previ-
ously published protocol [22]. This group was fed a 4% choles-
terol-l% choline diet (by weight) (Teklad Premier, Madison,
Wisconsin, USA) which has been shown to primarily increase
serum total cholesterol (TC) without affecting serum triglycer-
ides (TG), and to exacerbate aminonucleoside-induced FGS [9].
Eight male, 150 to 200 g Sprague-Dawley rats which received
seven subcutaneous injections of normal saline over 10 weeks
and were fed normal rat chow and water ad libitum served as
controls (Group 2). Four weeks after the last injection all the
animals were sacrificed by exsanguination under anesthesia.
Serum was collected for creatinine (Cr), albumin (AIb), TC,
TG, high density lipoprotein (HDL) and LDL, and renal tissue
was obtained for histology, immunohistochemistry, histochem-
istry and glomerular isolation. Prior to sacrifice the animals
were housed in metabolic cages for 24 hours and urine for
protein excretion was collected.
Modification of lipoproteins
Reactive fatty acid oxidation products (OP) were generated
by thermal autoxidation of arachidonic acid or linoleic acid [23].
Ten milligrams arachidonic acid were transferred to a glass vial
open to air and heated to 37°C for 72 hours. The yellow-brown
products were dissolved in Dulbecco's PBS with 300 LM EDTA
at pH 7.4, and aliquots containing the residue from 0.8 to 1.5 mg
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of oxidized fatty acid were added to 1 mg LDL or bovine
albumin in 1 ml Dulbecco's PBS containing 300M EDTA and
50 j.M butylated hydroxytoluene. Irreversible derivatization of
proteins occurred within minutes at 20°C; mixtures of protein
and oxidation products were washed repeatedly with PBS on
Amicon Centricon 30 microconcentrators to remove soluble
non-bound materials. Linoleic acid oxidation products were
obtained by heating to 100°C for 72 hours. The same procedure
that was used with arachidonic acid oxidation products was
followed for modification of LDL or albumin with linoleic acid
oxidation products. Copper-oxidized LDL was prepared by
incubating 200 pg/mI LDL in Dulbecco's PBS containing 5 M
CuSO4 for 24 hours. This yielded an extensively oxidized LDL
with an electrophoretic mobility in agarose about 3.5 times
greater than that of native LDL, more than 70% decrease in the
content of arachidonic acid and linoleic acid, and derivatization
of 40 to 50% of lysine amino groups [23—25]. Malondialdehyde-
LDL was prepared essentially as described by Fogelman and
colleagues [26]. Malondialdehyde stock solution (0.2 mM) was
generated by hydrolysis of 164 j.d tetramethoxypropane with
200 d 12 N HCL. After 1.5 minutes, the mixture was diluted
with 4.6 ml 0.1 ss sodium phosphate and then pH was adjusted
to 6 with 10 N NaOH. Equal volumes of malondialdehyde stock
solution and LDL were mixed and incubated at 37°C for three
hours, and then dialyzed to remove excess malondialdehyde.
Production of monoclonal antibodies to modWed lipoproteins
Antibodies against arachidonic or linoleic acid oxidation
product-modified LDL were generated by immunizing balb/c
mice with 50 pg oxidation product-modified human LDL in
Freund's complete adjuvant subcutaneously, and then four or
five injections of 50 pg oxidation product-modified human LDL
in Freund's incomplete adjuvant at 14-day intervals. Three days
before fusion the mice received an intravenous injection of 100
pg oxidation product-modified human LDL via the tail vein.
Splenocytes were fused with NS-l myeloma cells, and hybrid-
omas were selected and cloned according to previously de-
scribed techniques [27]. To identify clones specific for adducts
of oxidation products with lysine residues, and not for human
apolipoprotein B, primary screening of hybridoma supernatants
was performed by ELISA by using 96-well plates coated with
the corresponding oxidation product-modified bovine serum
albumin. An identical immunization protocol was used to obtain
antibodies against copper-oxidized LDL, except that the im-
munogen was copper-oxidized human LDL. To select hybrid-
omas specific for oxidized LDL, culture supernatants were
doubly screened against native LDL and oxidized LDL. Only
clones that produced antibodies reactive against oxidized LDL
but not native LDL were retained. Hybridomas were expanded
by intraperitoneal injection into pristane-primed balb/c mice.
Antibody class and subtype were determined with a commercial
ELISA typing kit (Bio-Rad, Richmond, California, USA).
For these studies, five monoclonal antibodies were selected.
One (AOP-7) is an 1gG2 antibody that specifically recognizes
lysine adducts of arachidonic acid oxidation products. The
specificity of this antibody is demonstrated in the competition
ELISA shown in Figure 1. Antibody AOP-7 showed partial
cross-reactivity with malondialdehyde LDL. LOP-23 is an IgG3
monoclonal antibody specific for proteins modified by linoleic
acid oxidation products (Fig. 1). Antibody AOP-24 is an 1gM
antibody that recognizes proteins modified with arachidonic
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Fig. 1. Specflcity of monoclonal antibodies to oxidized low-density
lipoprotein (Ox-LDL), Ascites fluid containing monoclonal antibody
together with the indicated concentration of competition was added to
microtiter wells coated with LDL modified by arachidonic acid oxida-
tion products (A and C), or linoleic acid oxidation products (B). Alter
overnight incubation, bound antibody was quantified as described in the
methods. A. Monoclonal antibody AOP-7 (1:8000 dilution). B. Mono-
clonal antibody LOP-23 (1:4000 dilution). C. Monoclonal antibody
AOP-24 (1:5000 dilution). Competing antigens were native LDL (0),
oxidized LDL (•), arachidonic acid oxidation product-modified LDL
(•), arachidonic acid oxidation product-modified bovine albumin (0),
and linoleic acid oxidation product-modified LDL (Li).
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Antibody dilution Antibody dilution
Fig. 2. Antibody dilution curves for monoclonal antibodies OX-lO (A) and OX-14 (B). Serial dilutions of ascites fluid containing monoclonal
antibody were incubated overnight on plates coated with native LDL (0), oxidized LDL (•), arachidonic acid oxidation product-modified LDL
(U), orarachidonic acid oxidation product-modified bovine albumin (LI). Bound antibody was then quantified as described in the Methods.
acid oxidation products, and also reacts with oxidized LDL
(Fig. 1). Antibodies OX-b and OX-14 are both 1gM antibodies
against copper-oxidized LDL. These 1gM antibodies tended to
show preferential binding to solid-phase antigen in competition
ELISA, and so their specificity was evaluated simply with
antibody dilution curves on plates coated with different antigens
(Fig. 2). OX-b and OX-l4 cross-reacted with proteins modified
by arachidonic acid oxidation products but did not bind to
native LDL.
Histology
Tissue was fixed in methyl Carnoy's solution and embedded
in paraffin. Three micron sections were stained with hematox-
ylin and eosin (H&E) and periodic acid-Schiff reagent (PAS).
Immunohistochemis try
The avidin-biotin-peroxidase complex procedure (Vector
Laboratories, Burlingame, California, USA) for antibody local-
ization was used as previously described [6]. To demonstrate
Ox-LDL, liquid nitrogen snap-frozen renal tissue fixed briefly in
4% buffered paraformaldehyde was incubated with mouse mono-
clonal antibodies (MoAb) specific for various products of oxi-
dation of LDL at a dilution of 1:200. To detect monocytes/
macrophages (MO) methyl Carnoy's-fixed paraffin-embedded
sections from all animals and snap-frozen sections from four
test rats were incubated with ED1 (Serotec, Oxford, UK), a
mouse monoclonal antibody specific for rat MO [28]. Human
atherosclerotic aorta and rat spleen served as positive tissue
controls for the demonstration of Ox-LDL and MO, respec-
tively.
It has been demonstrated that H202 with peroxidase can
modify LDL in vitro [29]. To avoid potential modification of
tissue LDL during the immunostaining procedure, the endoge-
nous peroxidase-quenching step utilizing H2O2 was performed
following the application of the secondary antibody when
staining for Ox-LDL.
Control studies were performed by substituting an irrelevant
MoAb for the primary MoAb and omitting incubation with the
primary MoAb.
Glomerular lipid analysis
Approximately 1.5 kidneys per rat were used for glomerular
lipid analysis. Glomeruli were obtained by differential sieving of
fresh renal cortex with stainless steel grids of varying mesh size
(grades 100, 150, and 200 in ascending order). The preparation
which was 90 to 95% pure was suspended in Ca k-free phos-
phate-buffered saline. Transport and isolation procedures were
carried out on ice to prevent the degradation of fatty acids. The
number of gbomeruli per sample was determined using a hemo-
cytometer. Total lipids were extracted by the method of Folch,
Lees and Stanley [301. The cholesterol concentration was
determined enzymatically [31] and phospholipid was assayed
from the content of lipid phosphorus [32]. Phospholipids were
resolved from other classes by thin layer plate chromatography
using petroleum ether/diethylether/acetic acid 85:15:3 (vollvol/
vol) as the solvent system. The phospholipids were recovered,
the fatty acids (PA) converted to their respective methyl esters
and separated, and quantified by gas liquid chromatography
[33]. The separation was accomplished using a Varian 3400 gas
liquid chromatograph equipped with a 30 m capillary column
and a Varian Star Integrator data handling system. The internal
standard in all samples was heptadecanoic acid (17:0).
Histochemistry
Snap-frozen renal cortex sections were fixed in 10% buffered
formalin and stained with oil red 0 for neutral lipid.
Biochemistry
Serum Cr, Alb, TC, TG, HDL, and LDL and urine protein
(U) were determined by standard hospital laboratory meth-
ods.
Statistics
Results are presented as mean values SD. Student's t-test
was used to compare means. A P value of less than 0.05 was
considered significant.
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Table 1. Mean values (± SD) ofmeasured serum and urine
biochemical parameters in Group I and 2 rats
Parameter Group 1 Group 2 P
Cr tirnolIliter 41 6 39 4 0.4191
Aib gluier 31 2 32 3 0.2872
Upr glday 0.37 0.19 0.02 0.01 <0.0001
TC mmollliter 15.06 6.17 1.66 0.024 <0.0001
TG mmollliter 2.42 1.05 2.04 1.15 0.4548
HDL mmol/liter 1.87 0.59 1.21 0.16 0.0063
LDL mmoll!iter 12.09 5.53 0 0 <0.0001
a p < 0.05 is considered significant (Student's t-test)
Results
General
Both groups of animals gained weight during the test period.
At the end of the experiment the mean body weight of Group 1
was 463 43 g while that of group 2 was 550 19 g, the
difference being significant (P < 0.0001). The kidney weights for
both groups were comparable (Group 1 = 4.33 1.00 g, Group
2 3.65 0.26 g, P 0.0784).
Biochemistry
Table 1 depicts the mean SD values for the parameters
evaluated in both groups. There was no significant difference in
renal function (Cr) between the two groups (Group 1 = 41 6
mol/1iter, Group 2 = 39 mol/liter, P = 0.4191). Urinary
protein excretion was significantly greater in Group 1 (Up =
0.37 0.19 g/day) than in Group 2 (U = 0.02 0.01 g!day; P
<0.0001). Mean serum Alb for Group 1 was 31 2g/liter while
that for Group 2 was 32 3 g/liter, the difference being
insignificant (P = 0.2872). Serum TC and LDL were much
higher in Group I (TC = 15.06 6.17 mmol/Iiter, LDL = 12.09
5.53 mmollliter) than in Group 2 [TC = 1.66 0.24 mmol/
liter, LDL = 0.00 0.00 mmol/liter (levels of LDL were too
low to be detected by our methods); P < 0.0001 for TC and
LDL]. Mean TG and HDL were also higher in Group 1 (TG =
2.42 1.05 mmol/Iiter, HDL = 1.87 0.59 mmol/liter) than in
Group 2 (TG = 2.04 1.15 mmoL1liter, HDL = 1.21 0.16
mmollliter) the difference being significant for HDL only (P =
0.0063 for HDL, P = 0.04548 for TG).
Histology
Between 147 and 420 glomeruli per animal were examined in
both groups. No obsolete glomeruli were observed in either
group. All animals in Group 1 demonstrated focal and segmen-
tal sclerotic lesions (Fig. 3) in between 6 and 50% of glomeruli
(mean = 19 13%). Most of the lesions were in an early stage
with the relatively mild mesangial matrix increase, prominence
of lining epithelial cells, presence of protein droplets in lining
visceral epithelial cells and the absence of glomerular hyalino-
sis. Fifty-one percent of the sclerotic glomerular lesions con-
tained one or more foam cells (FC). Segmental sclerotic lesions
were not observed in any of the control animals. Varying
degrees of focal atrophy and interstitial mononuclear cell infil-
tration and fibrosis were present in all test animals and in five of
eight control ones. The extent of the tubulointerstitial changes
was greater in Group 1 than in Group 2. Interstitial FC were not
observed in any of the animals. Varying degrees of neutral lipid
Fig. 3. Focal glomeruloscierosis. The glomerulus shows a relatively
early segmental sclerotic lesion at about 9 o'clock. A foam cell is
present within the lesion (arrowhead). (Hematoxylin and eosin, x250)
deposition in glomeruli was observed in all test rats but was not
present in the glomeruli of control animals. The mean propor-
tion of glomeruli per Group 1 rat containing oil red 0 material
was 63 23%.
linmunohistochemistry
Ox-LDL was demonstrated in glomeruli of the kidneys of all
members of Group 1, but in none of the Group 2 animals. The
lipid was present only in glomeruli (Fig. 4) and appeared to be
intracellular, The distribution of the Ox-LDL corresponded in
extent and distribution with the oil red 0 material. Glomerular
staining was positive for all five MoAbs used. The reactions for
the two monoclonal IgG antibodies (AOP = 7 and LOP = 23)
appeared stronger and more extensive than those for the three
monoclonal 1gM antibodies (AOP = 24, Ox = 10, Ox = 14). The
pattern of reaction with the anti-Ox-LDL MoAbs was granular
or punctate in most glomeruli with the reaction product dif-
fusely distributed within what appeared to be cellular cytoplasm
(Fig. 4). In some areas one or more small, clear vacuoles
coexisted with the reaction product. In occasional glomeruli the
reaction product was distributed peripherally around a large
vacuole (Fig. 4). The various reaction patterns were very
similar to those reported by Rosenfeld et a! for Ox-LDL in
atherosclerotic aortic lesions in WHHL rabbits [34].
Staining with ED! showed that the Group 1 animals had a
significantly higher mean intraglomerular MO count (2.4 1.1)
than did Group 2 rats (0.4 0.1; P < 0.0001, Fig. 5). Most but
not all FC were EDI positive. Comparison of the frozen kidney
sections from test rats stained with ED! to those stained for the
oxidized products demonstrated that the localization and dis-
tribution of ED! cells with features of FC appeared to be very
similar to that of the oxidized products within glomeruli.
Glomerular lipid analysis
Mean total cholesterol per glomerulus was higher in Group 1
(86.5 60.3 mol) than in Group 2 (64.9 77.0 mol), but the
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Fig. 4. Oxidized low-density lipoprotein (Ox-LDL) in glomeruli in rats with focal glomeruloscierosis. Immunohistochemical staining of kidney
tissue from test rats show intracellular localization of Ox-LDL in glomeruli using monoclonal antibodies AOP-7 (A) and LOP-23 (B).
(Immunoperoxidase, x 250).
Fig. 5. Intragloinerular monocytes in focal glornerulosclerosis (FGS),
Immunohistochemical staining for rat monocytes with ED1 shows
several ED1 + cells (arrowheads) in the glomerulus of a rat with FGS.
(Immunoperoxidase, x 250).
difference was not statistically significant. This was probably
due to the wide variation in glomerular lipid content demon-
strated by oil red 0 staining and possible glomerular count
error. Glomerular phospholipid content was very similar in both
groups (Group 1 = 46.5 28.1 zmo1Jglomerulus, Group 2 =
48.8 44.7 mol/gIomerulus). The ratio of total cholesterol to
phospholipid per glomerulus was significantly higher in Group 1
(1.82 0.66) than in Group 2 (1.14 0.50; P 0.0259).
The changes in cholesterollphospholipid ratio were associ-
ated with significant changes in the FA composition of the
glomerular phospholipids (Table 2). Within the family of satu-
rated FA, 16:0 was higher, although not significantly so, and
18:0 significantly lower in Group 1 animals (P = 0.0003). The
major mono-unsaturated FA, 18:1, was increased in Group 1
(12.8 0.3%) compared to controls (7.8 0.5%; P < 0.0001).
In the series of n-6 and n-3 FA, Group 1 rats had significantly
lower levels of the dietary essential FA 18:2n-6 (Group 1 = 11.9
1.0%, Group 2 = 13.5 1.1%, P 0.0047), but higher levels
of the longer chain more unsaturated homologues, 20:3 n-6
(Group 1 2.2 0.3%, Group 2 = 1.2 0.3%, P < 0.0001),
20:4 n-6 (Group 1 = 20.3 1.4%, Group 2 = 17.0 2.4%, P =
0.0011), and 22:5n-6 (Group 1 = 0.4 0.2%, Group 2 = 0.1
0.1%, P = 0.0004) than the control group. The higher levels of
longer chain n-6 FA in Group 1 was accompanied by a marked
reduction in the n-3 series FA 20:5n-3 (Group 1 = 0.0 0.0%,
Group 2 = 1.2 0.3%, P < 0.0001), 22:Sn-3 (Group 1 = 1.0
0.1%, Group 2 = 2.9 0.8%, P < 0.0001) in these animals. The
total carbon chain (C) 20 plus 22 n-3 FA's represented only 1.6
0.2% of total FA in Group 1 compared to 7.4 1.6% in the
Group 2 animals (P < 0.0001). The C20 + 22 n-6 FA were 27.4
1.4% of FA in Group I and 22.1 1.9% of FA in Group 2, the
difference being significant (P <0.0001). The changes in phos-
pholipid FA composition with decreased n-3 FA, especially
eicosapentaenoic acid (20:5n-3), and increase n-6, such as
arachidonic acid (20:4n-6) resulted in a much higher C20 + 22
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Table 2. Glomerular phospholipid fatty acid composition for Group 1
and 2 rats
Fatty acids % Group I Group 2 pb
Saturates
16:0 20.5 2.1 18.8 4.0 0.232
18:0 23.5 1.4 28.0 2.1 0.0003
20:0 0.2 0.1 0.3 0.1 0.0632
22:0 0.1 0.1 0.3 0.1 0.0104
24:0 0.4 0.1 0.6 0.1 0.0111
Mono-unsaturates
16:1 0.6 0.2 0.4 0.3 0.1471
18:1 12.8 0.3 7.8 0.5 <0.0001
20:1 0.8 0.1 0.3 0.1 0.0006
24:1 0.3 0.1 0.2 0.1 0.0403
n-6
18:2 11.9 1.0 13.5 1.1 0.0047
20:2 0.4 0.2 0.2 0.1 0.0051
20:3 2.2 0.3 1.2 0.3 <0.0001
20:4 20.3 1.4 17.0 2.4 0.0011
22:4 4.1 0.3 3.6 0.8 0.0708
22:5 0.4 0.2 0.1 0.1 0.0004
n-3
18:3 0.0 0.0 0.0 0.0
20:5 0.0 0.0 1.2 0.3 <0.0001
22:5 0.6 0.2 3.2 0.5 <0.0001
22:6 1.0 0.1 2.9 0.8 <0.0001
n-6 LCP 27.4 1.4 22.1 1.9 <0.0001
n-3 LCPa 1.6 0.2 7.4 1.6 <0.0001
n-6 LCP/n-3 LCP 17.8 1.7 3.1 0.5 <0.0001
Unsaturation 144 3 158 11 0.0005
index
a LCP, fatty acids with 20 and 22 carbons
b P < 0.05 is considered significant (Student's t-test)
n-6/n-3 ratio in Group 1 rats (17.8 1.7) than in Group 2 animals
(3.1 0.5; P < 0.0001).
Discussion
The significance of the finding of oxidatively modified
epitopes suggesting the presence of Ox-LDL in glomeruli in
experimental FGS is uncertain. There is considerable evidence
suggesting an important role for Ox-LDL in the pathogenesis of
atherosclerosis [19]. MO have been shown to play a key part in
the development of the fatty streak, the early lesion of athero-
sclerosis [35—37]. In animals fed an atherogenic, cholesterol rich
diet, there is arterial intimal infiltration by MO which take up
cholesteryl esters and form fatty streaks [35, 37]. Recently,
Rosenfeld et al have demonstrated that the foam cells in the
early atherosclerotic lesions in WHHL rabbits contain abun-
dant Ox-LDL [34] which has been shown to be taken up by a
"scavenger pathway" receptor distinct from the one responsi-
ble for the uptake of native LDL [38, 39]. Ox-LDL has been
shown to increase the adhesiveness of endothelial cells for MO
[40, 41] and vice versa [42]. Ox-LDL is a chemoattractant for
MO [43] and an inhibitor of macrophage motility [44], and thus
may mediate the MO infiltration and foam cell accumulation in
the fatty streak. Ox-LDL may also indirectly stimulate MO
chemotaxis by inducing monocyte chemoattractant protein 1
(MCP-l) in endothelial cells and JE (murine counterpart of
MCP- 1) expression in vivo in mice [45, 46]. Moreover, Ox-LDL
have been shown to be cytotoxic [47, 48], and it has been
suggested that these molecules may cause endothelial injury
and denudation thought to be an important factor in experimen-
tal atherogenesis [19]. Probucol, a powerful antioxidant, retards
the rate of progression of lesions in experimental atherosclero-
sis in rabbits [49, 50]. In view of the close similarity between
FGS and atherosclerosis it does not seem unreasonable to
speculate that glomerular Ox-LDL may mediate, at least in
part, the development of the segmental sclerotic lesions in
much the same way as has been shown for atherosclerosis.
Native LDL is susceptible to oxidation in vitro by cultured
endothelial cells, arterial smooth muscle cells and MO [48, 51,
52]. Shapiro and Xie have demonstrated that guinea pig mesan-
gial cells can modify native LDL in culture by a lipoxygenase-
dependent pathway [53], thus providing at least one source of
LDL oxidation in glomeruli. Whether the endothelium and MO
contribute to the process in glomeruli is unknown. Rat glomer-
uli and cultured mesangial cells preferentially bind Ox-LDL
[54].
In WHHL rabbits the oxidatively modified protein is largely
confined to the cytoplasm of intimal MO-derived foam cells in
the early atherosclerotic lesions, and to both intimal foam cells
and smooth muscle cells in the transitional lesions [34]. This
closely corresponds to the findings of the present study in that
the great majority of the glomerular lesions were relatively early
and the oxidatively modified epitopes were observed exclu-
sively within the cytoplasm of some glomerular cells, most of
which were phenotypically foam cells. The intracellular accu-
mulation of Ox-LDL in macrophages may be explained, at least
in part, by increased resistance of Ox-LDL to catheptic degra-
dation [551.
In this study the glomeruli of animals with FGS contained
Ox-LDL and increased amounts of arachidonic acid. This is
consistent with the observations that uptake of Ox-LDL by
cultured rat mesangial cells and mouse peritoneal macrophages
stimulates series 2 eicosanoid production [54, 56], and that
administration of an antioxidant, probucol, to cholesterol-fed
rats inhibits elaboration of these particular eicosanoids [57]. A
possible explanation for the increased arachidonic acid might be
to compensate for the altered membrane fluidity that could
result from increased membrane cholesterol and/or decreased
n-3 long chain fatty acids.
A high cholesterol diet has been shown to exacerbate exper-
imental FGS [9, 12, 58]. While the precise mechanisms for this
have not been completely elucidated, several factors such as
increased intraglomerular MO infiltration [9, 52, 59] which has
been shown to mediate, at least in part, glomerular injury in one
model of FGS [13], hypercholesterolemic-induced hyperviscos-
ity [60], and increased glomerular capillary pressure (PGC) [12]
have been implicated. The results of the phospholipid fatty acid
composition analysis in the present study are relevant to the
latter mechanism. Several experimental studies suggest an
association between hypercholesterolemia and glomerular lev-
els of series 2 eicosanoids such as PGE2 and TXB2 [57, 61, 621.
In one of these investigations the cholesterol-associated eleva-
tion in was linked to increased glomerular production of
TXB2 [57]. In the present study glomerular arachidonic acid
(20:4n-6) was increased and eicosapentaenoic acid (20:Sn-3)
was decreased in the hypercholesterolemic animals with FGS.
These results are consistent with those of the experiments
mentioned above [57, 61, 62], as arachidonic acid is the precur-
sor of series 2 eicosanoids [63].
In conclusion, the results of this study suggest that Ox-LDL
Magil et a!. Oxidized LDL in FGS 1249
is present in glomeruli in experimental FGS and is largely
localized to foam cells, many of which were observed in
segmental sclerotic lesions. While this observation does not
prove a pathogenetic role for Ox-LDL in this model of FGS, it
does significantly strengthen the concept of FGS being analo-
gous to atherosclerosis.
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